Recently, Walking Fish Therapeutics announced that it has completed a Series A financing of US$50 million. The company will use the funds obtained to develop B-cell therapies for the treatment of cancer, rare diseases, autoimmune diseases, as well as the development of regenerative therapies and the manufacture of recombinant antibodies.

Usually when we mention cell therapy, the first thing we think of is CAR-T and TCR-T cell therapy produced by genetic engineering of T cells. And Walking Fish Therapeutics company will focus on the research and development of B cells. Natural B cells have a strong ability to produce antibodies. The goal of Walking Fish is to use the ability of B cell protein production to make them become "factories" for protein production in the body through genetic engineering modifications to B cells. These B cells can be directed to target specific tissues.

Genetically engineered B cells can produce antibodies for the treatment of infectious diseases, and produce proteins for patients with genetic diseases that lack specific proteins. B cells also have a good antigen presentation function, so they also have broad potential in enhancing the anti-cancer immune response.